Basic information
Biomarker: POLE
Histology type: endometrial carcinoma
Cohort characteristics
Study type: Meta-Analysis
Followed up time :
Subgroup 1 name : POLE mutation
Subgroup 1 number: 48
Subgroup 2 name: POLE wild-type
Subgroup 2 number: 740
| Total number | Group I | Group I number | Group II | Group II number | Group III | Group III number | Group IV | Group IV number |
|---|---|---|---|---|---|---|---|---|
Sample information
Conclusion: POLE proofreading mutations predict favorable EC prognosis, independently of other clinicopathological variables, with the greatest effect seen in high-grade tumors. This novel biomarker may help to reduce overtreatment in EC.
Sample method: Meta-Analysis
Expression pattern : POLE proofreading mutations
Disease information
Related information
UniProt Link:
Molecular function from UniProt:
Survival figure legend: Cumulative probability of recurrence (A) and cancer-specific survival (B) according to POLE proofreading mutation in the combined PORTEC studies.$Cumulative probability of recurrence (A) and cancer-specific survival (B) according to POLE proofreading mutation in patients with grade 3 tumors in the combined PORTEC studies. P
Survival curve link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301706/figure/F1/$https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301706/figure/F2/
